These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34113337)

  • 21. HLA-DQA1 and HLA-DQB1 Alleles, Conferring Susceptibility to Celiac Disease and Type 1 Diabetes, are More Expressed Than Non-Predisposing Alleles and are Coordinately Regulated.
    Farina F; Picascia S; Pisapia L; Barba P; Vitale S; Franzese A; Mozzillo E; Gianfrani C; Del Pozzo G G
    Cells; 2019 Jul; 8(7):. PubMed ID: 31331105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA class II alleles in Norwegian patients with coexisting type 1 diabetes and celiac disease.
    Viken MK; Flåm ST; Skrivarhaug T; Amundsen SS; Sollid LM; Drivvoll AK; Joner G; Dahl-Jørgensen K; Lie BA
    HLA; 2017 May; 89(5):278-284. PubMed ID: 28247576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis: disease modifying therapy and the human leukocyte antigen.
    Werneck LC; Lorenzoni PJ; Kay CSK; Scola RH
    Arq Neuropsiquiatr; 2018 Oct; 76(10):697-704. PubMed ID: 30427510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence.
    Koudriavtseva T; Plantone D; Mandoj C; Giannarelli D; Latini A; Colafigli M; Trento E; Cordiali-Fei P; Pimpinelli F
    J Neurovirol; 2017 Feb; 23(1):147-151. PubMed ID: 27431677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
    Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
    Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term use of interferon-β in multiple sclerosis increases Vδ1
    Maimaitijiang G; Watanabe M; Shinoda K; Isobe N; Nakamura Y; Masaki K; Matsushita T; Yoshikai Y; Kira JI
    J Neuroinflammation; 2019 Sep; 16(1):179. PubMed ID: 31519178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
    Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
    CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex.
    Taheri M; Ghafouri-Fard S; Solgi G; Sayad A; Mazdeh M; Omrani MD
    Cytokine; 2017 Aug; 96():138-143. PubMed ID: 28399486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
    Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
    Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional characteristics of CD4+ T cells in multiple sclerosis: relative lack of suppressive populations in blood.
    Edström M; Mellergård J; Mjösberg J; Jenmalm M; Vrethem M; Press R; Dahle C; Ernerudh J
    Mult Scler; 2011 Jan; 17(1):57-66. PubMed ID: 20847001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.
    Coenen M; Hinze AV; Mengel M; Fuhrmann C; Lüdenbach B; Zimmermann J; Dykstra V; Fimmers R; Viviani R; Stingl J; Holdenrieder S; Müller M; Hartmann G; Coch C
    BMC Pharmacol Toxicol; 2015 Sep; 16():25. PubMed ID: 26392348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
    de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-DQ-restricted CD4+ T cells specific to streptococcal antigen present in low but not in high responders.
    Kamikawaji N; Fujisawa K; Yoshizumi H; Fukunaga M; Yasunami M; Kimura A; Nishimura Y; Sasazuki T
    J Immunol; 1991 Apr; 146(8):2560-7. PubMed ID: 1673141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta.
    Martínez-Aguilar L; Pérez-Ramírez C; Maldonado-Montoro MDM; Carrasco-Campos MI; Membrive-Jiménez C; Martínez-Martínez F; García-Collado C; Calleja-Hernández MÁ; Ramírez-Tortosa MC; Jiménez-Morales A
    Mutat Res Rev Mutat Res; 2020; 785():108322. PubMed ID: 32800273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis.
    Sørensen TL; Sellebjerg F
    Mult Scler; 2002 Apr; 8(2):104-7. PubMed ID: 11990865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.